Clinical trials: Cisplatin, completed
Head and Neck Cancer
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00265941
- Testing
- cetuximab, cisplatin, Accelerated Fractionation by Concomitant Boost
- Where
- 372 sites in United States, Canada
- Volunteers
- 940 people
- Sponsor
- Radiation Therapy Oncology Group
Squamous Cell Carcinoma of the Oral Cavity
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
This trial is to investigate the use of nivolumab in sequence with standard of care surgery and radiation/chemoradiation in locally advanced oral cavity Squamous cell carcinoma of the oral cavity.
- Trial name
- NICO (NCT03721757)
- Testing
- Nivolumab, Surgery, Radiotherapy, Nivolumab, Surgery, Chemoradiotherapy
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Gastric Cancer, Peritoneal Carcinomatosis
Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis
Phase I study on the maximum tolerated dose (MTD) and the recommended dose (RD) of intraperitoneal docetaxel combined with intravenous cisplatin and oral TS-ONE in gastric cancer patients with peritoneal carcinomatosis
- Trial name
- NCT02024841
- Testing
- Intraperitoneal docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The University of Hong Kong
Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
The probability to achieve CR with R-chemotherapy in patients failing a rituximab containing first line regimen is quite low, in particular in cases with non GCB profile.
- Trial name
- FIL_VERAL12 (NCT01805557)
- Testing
- R-DHAP, BR-DHAP
- Where
- 24 sites in Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Gastric Cancer
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of…
- Trial name
- NCT00675194
- Testing
- Cisplatin, Irinotecan, Capecitabine
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Johannes Gutenberg University Mainz
Multiple Myeloma
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial.
- Trial name
- NCT00083551
- Testing
- Thalidomide, Ara-C, BCNU
- Where
- United States
- Volunteers
- 668 people
- Sponsor
- University of Arkansas
Germ Cell Tumors, Measurable Disease
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent…
- Trial name
- Pazotest-01 (NCT01743482)
- Testing
- Pazopanib
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Urothelial Carcinoma
Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma
Pemetrexed has demonstrated a favorable response with minimal toxicity when used as single agent as first-line and second-line treatment for advanced urothelial carcinoma.
- Trial name
- PECULIAR (NCT01490437)
- Testing
- Pemetrexed, Cisplatin, Dexamethasone
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Asan Medical Center
Non-small Cell Lung Cancer
Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
Primary objective: functional imaging and quantitative imaging detection of the effects of Endostar combined with chemotherapy and radiotherapy on Non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01687439
- Testing
- Endostar, Vinorelbine, Cisplatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer
Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel
The study compares two combinations of chemotherapy in patients with advanced or metastatic NSCLC: 50% of the patients are treated with cisplatin and docetaxel, the other 50% with oxaliplatin and docetaxel.
- Trial name
- Taxelox (NCT01222312)
- Testing
- Cisplatin, Oxaliplatin, Docetaxel
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Krankenhaus Nordwest
Gastric Cancer
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior…
- Trial name
- AVATAR (NCT00887822)
- Testing
- Bevacizumab, Capecitabine, Cisplatin
- Where
- 14 sites in China
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC]…
- Trial name
- NCT03519971
- Testing
- Durvalumab, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel
- Where
- 86 sites in Brazil, Czechia and 12 more
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Adjuvant CCRT vs CT in Minimal N2 NSCLC
This study propose adjuvant concurrent chemoradiotherapy vs chemotherapy alone in completely resected microscopic N2 NSCLC
- Trial name
- NCT01066234
- Testing
- concurrent chemoradiotherapy, chemotherapy only
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Samsung Medical Center
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma is palliative and usually platinum based, and the patients often present with poor physical condition.
- Trial name
- NIVOTAX (NCT04282109)
- Testing
- Nivolumab + Paclitaxel, Cetuximab + Paclitaxel
- Where
- 21 sites in Spain
- Volunteers
- 141 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00310011
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to…
- Trial name
- NCT00003809
- Testing
- cetuximab, cisplatin
- Where
- 76 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan.
- Trial name
- NCT00314678
- Testing
- Topotecan, Cisplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- John P. Fruehauf
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Head and Neck Cancer
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
The phase I trial aims to determine the recommended phase II dose (RP2D) and schedule of olaparib in combination with standard cisplatin-based chemoradiotherapy, in patients with high-risk locally advanced squamous cell carcinoma…
- Trial name
- ORCA-2 (NCT02308072)
- Testing
- Olaparib, Cisplatin, IMRT
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Locally Advanced Cervical Cancer
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With…
- Trial name
- CALLA (NCT03830866)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 770 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.